Advertisment

Sanofi Unveils 12 Potential Blockbuster Drug Candidates Amid Increased Research Spending

author-image
Medriva Correspondents
New Update
NULL

Sanofi Unveils 12 Potential Blockbuster Drug Candidates Amid Increased Research Spending

Advertisment

Sanofi's Billion-Dollar Drug Candidates

Advertisment

Sanofi, a leading global biopharmaceutical company based in France, recently announced that it has 12 drugs currently under development that possess the potential to generate over $1 billion in annual sales. This announcement comes amid mounting pressure from investors, as the company has foregone profitability targets in favor of increased spending on research and development.

Boosting Drug Development Spending

In a move that has raised eyebrows among investors, Sanofi has planned to increase its drug development expenditure by approximately 700 million euros ($754 million) next year. This marks the first time the company has specified an increase in costs, a move that had previously led to a stock sell-off in late October. CEO Paul Hudson projected that the 'steady state' of longer-term development expenses would likely be between 700 million and 1 billion euros above the 2023 level.

Advertisment

A Glimpse into the Potential Blockbusters

Among the 12 drug candidates, nine have been identified as potential medicines and vaccines with a peak sales potential of 2-5 billion euros ($2.2-$5.4 billion), according to a statement released by Sanofi. The company also expects its recently launched and future pharmaceutical assets to generate more than 10 billion euros of annual sales by 2030. The top-selling anti-inflammatory drug Dupixent, which Sanofi aims to use in treating chronic obstructive pulmonary disease (COPD), also known as 'smoker's lung', is anticipated to deliver low double-digit annual sales growth up to 2030.

Accelerating Growth through Pipeline Transformation

Advertisment

Sanofi is currently hosting an Investor R&D Event in New York, offering updates and insights into its innovative pipeline and new growth drivers. The company's commitment to R&D is expected to drive a 50% increase in the number of Phase 3 studies between 2023 and 2025, marking the greatest pipeline momentum in Sanofi's history. This commitment will also support an anticipated 25 mid to late-stage readouts and up to 19 regulatory submissions for its pharmaceutical assets over the next two years.

Sanofi's Ambitious Plans Amid Profit Warning

Following a profit warning in late October that resulted in a $25 billion reduction in market value, Sanofi has outlined ambitious plans to strengthen its pipeline of new medicines. An increase in drug development investments will help Sanofi to generate more than €10 billion ($11 billion) in annual sales from future and recently launched medicines by 2030, according to the company's projections.

Advertisment
Chat with Dr. Medriva !